Welcome to our dedicated page for bioAffinity Tech news (Ticker: BIAFW), a resource for investors and traders seeking the latest updates and insights on bioAffinity Tech stock.
News about bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) centers on its work in noninvasive lung cancer diagnostics and related lung disease research. The company’s disclosures describe CyPath® Lung, a sputum-based test that uses advanced flow cytometry and artificial intelligence (AI) to detect cell populations indicative of malignancy. Clinical data reported by bioAffinity show high sensitivity, specificity and accuracy for detecting lung cancer in high-risk patients with small lung nodules, including cases identified at Stage 1A.
Readers following BIAFW news will see updates on clinical and real-world case studies where CyPath® Lung contributed to early diagnosis or helped avoid unnecessary invasive procedures. Company announcements also highlight presentations at professional meetings, such as pulmonary and cancer-focused conferences, where research on CyPath® Lung’s processing methods, sample handling and diagnostic performance is shared with clinicians and researchers.
Another key news theme is laboratory quality and accreditation. bioAffinity reports that its subsidiary Precision Pathology Laboratory Services (PPLS) maintains College of American Pathologists (CAP) accreditation and CLIA certification, which the company associates with quality, accuracy and patient safety across its diagnostic services, including CyPath® Lung.
Investors and healthcare professionals can also expect news on intellectual property developments, such as U.S. and international patents covering the AI-built diagnostic algorithm and the broader flow cytometry platform for assessing lung health and multiple lung diseases. In addition, corporate and financial news items describe equity financings, warrant-related transactions, and commentary from management linking revenue trends and operating decisions to the commercialization of CyPath® Lung.
For those tracking BIAFW, the news flow provides context on how bioAffinity is advancing its noninvasive diagnostic platform, expanding clinical use of CyPath® Lung, and managing its capital structure and Nasdaq listing status.
bioAffinity Technologies (NASDAQ: BIAF; BIAFW) recently announced the award of multiple patents in China, Mexico, and Australia for novel porphyrin conjugated compounds aimed at selective cancer treatment. These patents, valid until 2037, underscore the company's commitment to innovative cancer therapies, particularly as cancer rates rise in these regions. The company’s flagship product, CyPath® Lung, shows high sensitivity and specificity in early lung cancer detection, indicating strong potential for both diagnostic and therapeutic advancements in oncology.
bioAffinity Technologies (NASDAQ: BIAF; BIAFW) is set to present its research on using flow cytometry for diagnosing lung diseases at the CHEST 2022 conference from Oct. 16-19, 2022. The presentation, led by PhD Lydia Bederka, will focus on Sputum Analysis By Flow Cytometry To Assess Lung Health on Oct. 19, highlighting the development of its product, CyPath® Lung, which detects early-stage lung cancer with 92% sensitivity and 87% specificity.
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) has secured approximately
bioAffinity Technologies (NASDAQ: BIAF, BIAFW) announced a publication in PLOS ONE regarding their flow cytometry research on sputum analysis for lung health diagnostics. The study introduces an innovative method for detecting lung cancer and potentially other diseases like COPD and asthma. President and CEO Maria Zannes emphasized the significance of this noninvasive diagnostic approach, stating it may enhance overall diagnostic accuracy, reduce unnecessary procedures, and lower medical costs. bioAffinity's CyPath® Lung test, known for its high sensitivity and specificity, supports early lung cancer detection.
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) announced the successful completion of its IPO, raising approximately